The following is the desk’s recommended decision sequence, not a claim that every supplier offers these protections.
| Decision | Evidence to assemble | Commercial consequence |
|---|---|---|
| Establish route eligibility | Product, presentation, dispensing entity, destination states and applicable legal assessment | Exclude unresolved routes from the approved commercial shortlist |
| Identify controllable spending | Redacted invoices, payment flows and current contracts | Separate patient savings from clinic margin improvements |
| Obtain matched quotations | Dose-mix assumptions supplied by clinical leadership; days supplied; all service charges; price-validity date | Prevent starter prices or omitted fees from determining the winner |
| Test continuity | Capacity evidence, exception reporting, escalation ownership and a transfer plan | Prefer verifiable service obligations over unsupported availability claims |
| Reconcile the 2027 boundary | Applicable offer expirations and list-price changes | Avoid carrying November terms into the next budget without confirmation |
| Limit stranded commitments | Cancellation, clinical-stop, regulatory-change and patient-transition provisions | Make commitment exposure visible before approval |
Recommended negotiating position: seek transparency on fees, fulfillment performance, data access and exit arrangements before trading flexibility for a medicine-price headline. Keep clinical selection independent of the financial model.
Explore the table row by row
A working view of the research
Establish route eligibility
- Evidence to assemble
- Product, presentation, dispensing entity, destination states and applicable legal assessment
- Commercial consequence
- Exclude unresolved routes from the approved commercial shortlist
Sources cited on this page
See the section’s source register for the research context.
Section sources →